Lotus Eye Hospital and Institute enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


229	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.8	1.8	2.0	2.7	3.6
11.4	11.4	0.0	0.0	0.0
238	—	—	—	—
9.6	9.6	−2.0	−2.7	−3.6
₹114.63	—	—	—	—

71.6	71.6	60.0	59.4	57.6
16.0%	16.0%	0.0%	0.0%	0.0%
0.05×	—	—	—	—

4.16×	—	—	—	—
49.14×	—	—	—	—
834.67×	—	—	—	—
57.3	53.7	49.6	48.2	47.0
4.9	3.4	3.4	6.5	7.6
0.3	−0.4	0.4	2.8	4.6
—	3.1	4.9	5.7	4.4
−9.9	−9.9	0.1	0.0	1.3
—	−10.4	−0.0	0.0	1.3
—	13.0	4.8	5.6	3.1

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

LOTUSEYE₹110.00

Lotus Eye Hospital and Institute Limited

· Pharma & Health

₹ CrorePeersGPTHEALTH GKSL SHALBY INDRAMEDCO ARTEMISMED DRAGARWQ KMCSHIL KOVAIMcap ₹229 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	228.8
- Cash, Equiv & ST Investments	3.6	2.7	2.0	1.8	1.8
+ Total Debt	0.0	0.0	0.0	11.4	11.4
Enterprise Value	—	—	—	—	238.4
Net Debt (memo)	-3.6	-2.7	-2.0	9.6	9.6
EV per Share	—	—	—	—	114.63

Total Capital	57.6	59.4	60.0	71.6	71.6
Total Debt/Total Capital	0.00	0.00	0.00	15.97	15.97
Total Debt/EV	—	—	—	—	0.05

EV/Sales	—	—	—	—	4.16
EV/EBITDA	—	—	—	—	49.14
EV/EBIT	—	—	—	—	834.67
Reference Items — Trailing FY Values
Sales	47.0	48.2	49.6	53.7	57.3
EBITDA	7.6	6.5	3.4	3.4	4.9
EBIT	4.6	2.8	0.4	-0.4	0.3
Operating Cash Flow	4.4	5.7	4.9	3.1	—
Free Cash Flow	1.3	0.0	0.1	-9.9	-9.9
FCFF (free cash flow to the firm)	1.3	0.0	-0.0	-10.4	—
Capital Expenditure	3.1	5.6	4.8	13.0	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.